Halozyme Non Current Assets Total from 2010 to 2024
| HALO Stock | USD 48.20 0.27 0.56% |
Non Current Assets Total | First Reported 2002-06-30 | Previous Quarter 981.7 M | Current Value 991.1 M | Quarterly Volatility 339.5 M |
Check Halozyme Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Halozyme Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.1 M, Interest Expense of 19.7 M or Selling General Administrative of 156.6 M, as well as many indicators such as Price To Sales Ratio of 5.59, Dividend Yield of 0.0 or PTB Ratio of 55.27. Halozyme financial statements analysis is a perfect complement when working with Halozyme Therapeutics Valuation or Volatility modules.
Halozyme | Non Current Assets Total |
Latest Halozyme Therapeutics' Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Halozyme Therapeutics over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Halozyme Therapeutics' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Halozyme Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
Halozyme Non Current Assets Total Regression Statistics
| Arithmetic Mean | 227,015,137 | |
| Geometric Mean | 20,083,994 | |
| Coefficient Of Variation | 187.01 | |
| Mean Deviation | 325,931,585 | |
| Median | 10,017,000 | |
| Standard Deviation | 424,545,024 | |
| Sample Variance | 180238.5T | |
| Range | 1.1B | |
| R-Value | 0.73 | |
| Mean Square Error | 90324.4T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 69,413,923 | |
| Total Sum of Squares | 2523338.7T |
Halozyme Non Current Assets Total History
About Halozyme Therapeutics Financial Statements
Halozyme Therapeutics investors utilize fundamental indicators, such as Non Current Assets Total, to predict how Halozyme Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 986.8 M | 1 B |
Pair Trading with Halozyme Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Halozyme Stock
Moving against Halozyme Stock
| 0.6 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.59 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.58 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.47 | GANX | Gain Therapeutics | PairCorr |
| 0.44 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.
The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Halozyme Therapeutics Correlation against competitors. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.02 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.